Group 1 - The core viewpoint of the articles indicates that Meihao Medical's stock closed at 24.15 yuan, down 1.43%, with a rolling PE ratio of 27.46 times and a total market value of 9.821 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 48.71 times and a median of 35.37 times, Meihao Medical ranks 62nd in terms of PE ratio [1][2] - The main business of Shenzhen Meihao Chuangyi Medical Technology Co., Ltd. includes the design, development, manufacturing, and sales of precision components and products for medical devices [1] Group 2 - For the first quarter of 2025, Meihao Medical reported an operating income of 296 million yuan, a year-on-year increase of 5.05%, and a net profit of 51.875 million yuan, a year-on-year decrease of 10.62%, with a gross profit margin of 39.28% [1] - The company is recognized as a national high-tech enterprise and a national intellectual property advantage enterprise, and it is a champion in a specific manufacturing sector in Guangdong Province [1]

交易信息汇总 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 5月16日，美好医疗的资金流向情况如下：主力资金净流入458.8万元；游资资金净流入598.49万元；散 户资金净流出1057.3万元。 公司公告汇总 美好医疗发布了关于2024年限制性股票激励计划首次授予第一个归属期归属结果暨股份上市的公告。主 要内容如下：- 本次归属股票的上市流通日为2025年5月16日，归属股票数量为123.6792万股，占公司总 股本的0.30%，归属人数为154人。- 股票来源为公司自二级市场回购的A股普通股。- 公司根据2023年年 度股东大会授权，于2025年4月16日召开董事会和监事会审议通过相关议案，确认首次授予第一个归属 期归属条件已成就。- 首次授予的限制性股票的授予价格为12.42元/股，调整后为12.26元/股。- 首次授 予的激励对象中9人因个人原因离职，其已获授但尚未归属的限制性股票共计17.20万股作废。- 公司层 面业绩考核指标达到触发值但未达到目标值，公司层面归属比例为80%，作废30.9198万股。- 首次授予 日为 ...

Core Viewpoint - The announcement details the implementation of the 2024 Restricted Stock Incentive Plan by Shenzhen Meihua Chuangyi Medical Technology Co., Ltd, highlighting the first vesting results and the listing of shares [1][19]. Summary by Relevant Sections Stock Incentive Plan Overview - The total number of shares for this vesting is 1,236,792 shares, accounting for 0.30% of the company's total share capital [1]. - The number of participants in this vesting is 154 individuals [1]. - The shares are sourced from A-shares repurchased by the company from the secondary market [1]. Vesting Conditions and Arrangements - The first vesting period is set to begin on May 9, 2025, and will last until the last trading day within 24 months from the grant date [10]. - The vesting arrangement includes three periods: - First vesting period: 30% after 12 months - Second vesting period: 30% after 24 months - Third vesting period: 40% after 36 months [4][5]. Performance Assessment - The performance assessment for the first vesting period is based on the company's revenue and net profit growth rates, with specific target and trigger values set for 2024-2026 [5][10]. - The company achieved a revenue growth rate of 19.19% in 2023, with a net profit growth rate of 22.09% [10]. Adjustments and Cancellations - A total of 481,198 shares were canceled due to participants leaving the company and performance not meeting target values [9][11]. - The adjusted grant price for the shares is set at 12.26 yuan per share [8][14]. Listing and Trading Restrictions - The shares will be listed for trading on May 16, 2025 [15]. - There are restrictions on the transfer of shares held by directors and senior management, in accordance with relevant regulations [16]. Financial and Legal Compliance - The company has complied with necessary legal and regulatory requirements for the implementation of the incentive plan [18][19]. - The independent financial advisor confirmed that the plan's adjustments and vesting conditions have been properly reviewed and disclosed [18].

证券代码：301363 证券简称：美好医疗 公告编号：2025-037 深圳市美好创亿医疗科技股份有限公司 关于2024年限制性股票激励计划 首次授予第一个归属期归属结果暨股份上市的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： （一）股权激励计划简介 公司分别于2024年4月16日、2024年5月9日召开第二届董事会第十次会议、 2023年年度股东大会审议通过《关于<2024年限制性股票激励计划（草案）>及摘 要的议案》等相关议案，本激励计划的主要内容如下： （一）本次归属股票的上市流通日：2025年5月16日 （二）本次归属股票的数量：123.6792万股，占目前公司总股本的0.30% （三）本次归属人数：154人 （四）归属股票来源：公司自二级市场回购的A股普通股。 1、股权激励方式：第二类限制性股票。 2、股票来源：公司自二级市场回购和/或定向增发A股普通股。 3、授予数量：本激励计划授予限制性股票合计600.00万股，占本激励计划 公告时公司股本总额的1.48%。其中，首次授予532.53万股，占本激励计划公告 时公司股本总额的 ...

Business Overview - The company specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, aiming to provide a comprehensive one-stop service for global medical device enterprises [1][2]. - The company has established deep collaborations with numerous global medical device leaders in various fields, including respiratory health, hearing rehabilitation, blood glucose management, cardiovascular, and in vitro diagnostics [2]. Financial Performance - In 2024, the company achieved a revenue of CNY 1.594 billion, representing a year-on-year growth of 19.19%. The net profit attributable to shareholders was CNY 364 million, up 16.11% [32]. - The company plans to distribute a cash dividend of CNY 1.00 per 10 shares and to increase capital reserves by 4 shares for every 10 shares held [5]. Employee and R&D Statistics - As of December 31, 2024, the company had a total of 2,440 employees, with 465 in R&D, accounting for 19.06% of the workforce, an increase of 8.14% from the previous year [7]. - The R&D investment for 2024 was CNY 141 million, which is 8.82% of the total revenue, reflecting a 16.75% increase year-on-year [44]. Market Dynamics - The medical device industry does not exhibit significant seasonal fluctuations, with production and delivery based on customer demand forecasts [3]. - The company’s direct exports to the U.S. represent a low percentage of total revenue, and it has maintained stable growth despite U.S. tariffs [9][10]. Customer Concentration and Risks - The top five customers account for 82.32% of total sales, with the largest customer having a significant market presence. The company is aware of the risks associated with high customer concentration and is focused on diversifying its customer base [14]. Strategic Initiatives - The company is expanding its production capacity in Malaysia, with the third phase of its industrial base expected to be operational by the end of 2025, which will increase its overseas delivery capabilities [32][33]. - A new stock incentive plan for 2025 aims to grant 5 million restricted shares to support new business initiatives and international expansion [25]. Intellectual Property and Compliance - As of the end of 2024, the company held 263 authorized patents and 36 software copyrights, demonstrating its commitment to innovation and technology [21][22]. - The company adheres to strict compliance with information disclosure regulations to protect investor rights [26][27]. Future Outlook - The company plans to continue investing in new product development and market expansion, particularly in the fields of blood glucose management and automated production systems [47][48]. - The management emphasizes the importance of long-term value creation and encourages investors to focus on sustainable growth rather than short-term fluctuations [37][38].

深圳市美好创亿医疗科技股份有限公司 章 程 深圳市美好创亿医疗科技股份有限公 司 公司章程 目 录 深圳市美好创亿医疗科技股份有限公司 公司章程 深圳市美好创亿医疗科技股份有限公司 章 程 （2025 年 4 月修订） 第一章 总则 第一条 为维护深圳市美好创亿医疗科技股份有限公司（以下简称"公司" 或"本公司"）、股东和债权人的合法权益，规范公司的组织和行为，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司章程指引》《深圳证券交易所创业板 股票上市规则》和其他有关规定，结合公司的具体情况，制订本章程。 第二条 公司系依据《公司法》和其他有关规定成立的股份有限公司。 公司系在深圳市美好创亿医疗科技有限公司（以下简称"有限公司"）的基 础上，以整体变更方式发起设立的股份有限公司，在深圳市市场监督管理局注册 登记，取得营业执照，统一社会信用代码为"914403005586534068"。 第三条 经深圳证券交易所审核通过，并经中国证券监督管理委员会（以下 简称"中国证监会"）同意注册，公司首次向社会公众公开发行人民币普通股 第四条 公司注册 ...

深圳市美好创亿医疗科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 证券代码：301363 证券简称：美好医疗 公告编号：2025-036 统一社会信用代码：914403005586534068 类型：股份有限公司（上市、自然人投资或控股） 法定代表人：熊小川 成立日期：2010年07月15日 住所：深圳市龙岗区宝龙街道宝龙社区宝龙三路8号美好创亿大厦2号厂房 101-1701（一照多址企业） 《公司章程》同步修改，与上述内容保持一致。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）于2025年4月 16日召开的第二届董事会第十六次会议及2025年5月8日召开的2024年年度股东 大会审议通过了《关于拟增加董事会席位、申请一照多址并修订<公司章程>的议 案》，具体内容详见公司于2025年4月18日在巨潮资讯网（www.cninfo.com.cn） 披露的相关公告。 近日，公司已完成工商变更登记和《公司章程》备案等手续，并取得了深圳 市市场监督管理局换发的《营业执照》，《营业执照》的具体内容如下： ...

深圳市美好创亿医疗科技股份有限公司 章 程 2025 年 5 月 | | | | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 5 | | 第一节 | 股份发行 5 | | 第二节 | 股份增减和回购 6 | | 第三节 | 股份转让 7 | | 第四章 | 股东和股东大会 8 | | 第一节 | 股东 9 | | 第二节 | 股东大会的一般规定 11 | | 第三节 | 股东大会的召集 16 | | 第四节 | 股东大会的提案与通知 18 | | 第五节 | 股东大会的召开 19 | | 第六节 | 股东大会的表决和决议 23 | | 第五章 | 董事会 28 | | 第一节 | 董事 28 | | 第二节 | 董事会 32 | | 第六章 | 总经理及其他高级管理人员 37 | | 第七章 | 监事会 39 | | 第一节 | 监事 39 | | 第二节 | 监事会 40 | | 第八章 | 财务会计制度、利润分配和审计 42 | | 第一节 | 财务会计制度 42 | | 第二节 | 内部审计 45 | | 第三节 | 会计师事务所的 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Meihao Medical, which closed at 26.16 yuan with a PE ratio of 29.75 times, significantly lower than the industry average of 49.84 times [1][2] - Meihao Medical's total market capitalization is reported at 10.638 billion yuan, ranking 68th in the medical device industry based on PE ratio [1][2] - As of the first quarter of 2025, 30 institutions hold shares in Meihao Medical, with a total holding of 42.1394 million shares valued at 1.23 billion yuan [1] Group 2 - The main business of Shenzhen Meihao Chuangyi Medical Technology Co., Ltd. includes the design, development, manufacturing, and sales of precision components and products for medical devices [1] - Key products include home respiratory machine components, cochlear implant components, and other medical product components, positioning the company as a national high-tech enterprise [1] - The latest financial results for the first quarter of 2025 show revenue of 296 million yuan, a year-on-year increase of 5.05%, while net profit decreased by 10.62% to 51.875 million yuan, with a gross profit margin of 39.28% [1]

5月9日，美好医疗的资金流向如下：主力资金净流入1030.55万元，占总成交额11.41%；游资资金净流 入220.8万元，占总成交额2.44%；散户资金净流出1251.36万元，占总成交额13.85%。 公司公告汇总 美好医疗发布了关于2025年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告。报告指 出，公司拟实施2025年限制性股票激励计划，并对内幕信息知情人在本激励计划公开披露前6个月买卖 公司股票的情况进行了自查。核查对象为本激励计划的内幕信息知情人，均已填报《内幕信息知情人登 记表》。公司向中国证券登记结算有限责任公司深圳分公司申请查询核查对象于自查期间买卖公司股票 的情况，已出具《信息披露义务人持股及股份变更查询证明》和《股东股份变更明细清单》。本激励计 划公开披露前，公司严格按照《内幕信息知情人登记管理制度》相关规定，限定内幕信息知情人范围并 采取相应保密措施，未发现信息泄露情况。根据中国证券登记结算有限责任公司深圳分公司出具的查询 文件显示，核查对象于自查期间均不存在买卖公司股票的情况。备查文件包括中国证券登记结算有限责 任公司深圳分公司出具的《信息披露义务人持股及股份变更查询证明 ...